Home › Comparison
Retatrutide vs Semaglutide
A side-by-side comparison of two medicines being studied or used for weight management, with mechanism, development status and evidence kept clearly separated.
| Feature | Retatrutide Investigational | Semaglutide Approved products |
|---|---|---|
| Mechanism | Triple agonist: GLP-1, GIP and glucagon receptors. | GLP-1 receptor agonist. |
| Development | Investigational clinical development. | Approved medicines exist for specified indications. |
| Weight-management evidence | Clinical trials have reported weight-loss outcomes in study populations. | Clinical trials support approved weight-management indications for certain products. |
| Availability | Investigational. Lilly states retatrutide is not approved for public use and is being studied in clinical trials. | Approved products exist. Availability and indication depend on the specific semaglutide product, country and prescribing requirements. |
| Safety | Still being evaluated. Safety and tolerability continue to be studied as clinical development progresses. | Established regulatory information exists. Approved semaglutide products have product-specific contraindications, warnings and adverse-reaction information. |
Mechanism
Retatrutide targets three receptor pathways; semaglutide targets GLP-1.
Development
The two medicines sit at different stages of development and regulatory status.
Interpretation
Compare trials by population, dose, duration, endpoints and comparator rather than headline numbers alone.
Availability — what it means
“Availability” here refers to regulatory status and lawful public access, not whether a product can be found online. Retatrutide remains investigational; Lilly says it is not approved for public use. Approved semaglutide products have specific indications and prescribing requirements.
Safety — what to look for
Safety should be assessed from clinical-trial data and official prescribing information, including adverse reactions, contraindications, warnings and limitations. The evidence base is different for an investigational medicine and an approved product.